Northeast Pharmaceutical Group Co Ltd (000597) — Cash Flow-to-Debt Ratio
Northeast Pharmaceutical Group Co Ltd (000597) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥274.09 Million could theoretically repay 0% of its total liabilities (CN¥8.05 Billion) in one year. See Northeast Pharmaceutical Group Co Ltd (000597) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Northeast Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Northeast Pharmaceutical Group Co Ltd across 28 annual periods. For the full cash flow conversion analysis, see Northeast Pharmaceutical Group Co Ltd cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Northeast Pharmaceutical Group Co Ltd (1998–2025)
Year-by-year debt coverage analysis for Northeast Pharmaceutical Group Co Ltd. Check 000597 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | CN¥1.11 Billion | CN¥7.22 Billion | ▲ +79.3% |
| 2024 | 0.09x | CN¥758.76 Million | CN¥8.88 Billion | ▲ +47.4% |
| 2023 | 0.06x | CN¥586.75 Million | CN¥10.11 Billion | ▼ -52.4% |
| 2022 | 0.12x | CN¥1.11 Billion | CN¥9.10 Billion | ▲ +45.1% |
| 2021 | 0.08x | CN¥746.51 Million | CN¥8.89 Billion | ▲ +18.3% |
| 2020 | 0.07x | CN¥570.92 Million | CN¥8.04 Billion | ▲ +73.6% |
| 2019 | 0.04x | CN¥352.60 Million | CN¥8.62 Billion | ▲ +16.6% |
| 2018 | 0.04x | CN¥285.09 Million | CN¥8.13 Billion | ▲ +193.7% |
| 2017 | -0.04x | CN¥-301.20 Million | CN¥8.05 Billion | ▼ -171.6% |
| 2016 | 0.05x | CN¥384.51 Million | CN¥7.36 Billion | ▲ +229.9% |
| 2015 | 0.02x | CN¥99.70 Million | CN¥6.29 Billion | ▲ +96.0% |
| 2014 | 0.01x | CN¥46.99 Million | CN¥5.81 Billion | ▲ +118.1% |
| 2013 | -0.04x | CN¥-266.38 Million | CN¥5.96 Billion | ▼ -320.4% |
| 2012 | 0.02x | CN¥86.09 Million | CN¥4.24 Billion | ▲ +135.9% |
| 2011 | -0.06x | CN¥-233.32 Million | CN¥4.13 Billion | ▼ -178.1% |
| 2010 | 0.07x | CN¥255.96 Million | CN¥3.54 Billion | ▼ -52.7% |
| 2009 | 0.15x | CN¥615.91 Million | CN¥4.03 Billion | ▼ -45.4% |
| 2008 | 0.28x | CN¥709.03 Million | CN¥2.53 Billion | ▲ +205.2% |
| 2007 | 0.09x | CN¥198.56 Million | CN¥2.16 Billion | ▲ +210.9% |
| 2006 | -0.08x | CN¥-106.00 Million | CN¥1.28 Billion | ▼ -203.9% |
| 2005 | 0.08x | CN¥111.40 Million | CN¥1.40 Billion | ▼ -41.5% |
| 2004 | 0.14x | CN¥211.06 Million | CN¥1.55 Billion | ▼ -2.3% |
| 2003 | 0.14x | CN¥230.08 Million | CN¥1.65 Billion | ▲ +60.0% |
| 2002 | 0.09x | CN¥157.41 Million | CN¥1.81 Billion | ▲ +106.8% |
| 2001 | 0.04x | CN¥78.84 Million | CN¥1.87 Billion | ▲ +105.6% |
| 2000 | 0.02x | CN¥36.13 Million | CN¥1.76 Billion | ▼ -35.1% |
| 1999 | 0.03x | CN¥54.62 Million | CN¥1.73 Billion | ▲ +760.8% |
| 1998 | 0.00x | CN¥-7.59 Million | CN¥1.59 Billion | — |